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Summary
Background Studies assessing cardiovascular disease (CVD) risk factors in patients
with psoriasis have been limited by selection bias, inappropriate controls or a
reliance on data collected for clinical reasons.
Objectives To investigate whether screening for CVD risk factors in patients with
psoriasis in primary care augments the known prevalence of CVD risk factors in a
cross-sectional study.
Methods Patients listed as having psoriasis in primary care were recruited, screened
and risk assessed by QRISK2.
Results In total, 287 patients attended (mean age 53 years, 57% women, 94%
white British, 22% severe disease, 33% self-reported psoriatic arthritis). The pro-
portion with known and screen-detected (previously unknown) risk factors was
as follows: hypertension 35% known and 13% screen-detected; hypercholestero-
laemia 32% and 37%; diabetes 66% and 31% and chronic kidney disease 11%
and 45%. At least one screen-detected risk factor was found in 48% and two or
more risk factors were found in 21% of patients. One in three patients (37%)
not previously known to be at high risk were found to have a high (> 10%) 10-
year CVD risk. Among the participants receiving treatment for known CVD risk
factors, nearly half had suboptimal levels for blood pressure (46%) and choles-
terol (46%).
Conclusions Cardiovascular risk factor screening of primary care-based adults with
psoriasis identified a high proportion of patients (i) at high CVD risk, (ii) with
screen-detected risk factors and (iii) with suboptimally managed known risk fac-
tors. These findings need to be considered alongside reports that detected limited
responses of clinicians to identified risk factors before universal CVD screening
can be recommended.
What’s already known about this topic?
• Several studies have suggested that patients with psoriasis have a greater number of
risk factors for cardiovascular disease (CVD) and a higher risk for vascular events
compared with the general population.
• However, the prevalence data used to support systematic CVD risk factor screening
in psoriasis have been limited by selection bias, inappropriate choice of control
groups or reliance on risk factors measured for other clinical reasons.
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What does this study add?
• Cardiovascular risk factor screening of primary care-based adults with psoriasis
identified a high proportion of patients (i) at high CVD risk, (ii) with screen-
detected risk factors and (iii) with suboptimally managed known risk factors.
• These findings need to be considered alongside reports that detected limited
responses of clinicians to identified risk factors before universal CVD screening can
be recommended.
Several studies have suggested that patients with psoriasis have a
greater number of risk factors for cardiovascular disease (CVD)
and a higher risk for vascular events compared with the general
population.1 However, the prevalence data used to support sys-
tematic CVD risk factor screening in psoriasis have been limited
by selection bias, inappropriate choice of control groups or reli-
ance on risk factors measured for other clinical reasons.1–4
No previous primary care-based study has assessed how CVD
risk factor screening influences the estimated prevalence of CVD
risk factors in patients with psoriasis or estimated the potential
benefits of CVD risk factor identification or intervention.
Our aims were (i) to investigate whether CVD risk factor
screening in primary care could influence the estimated preva-
lence of CVD risk factors in patients with psoriasis, (ii) to
assess whether the prevalence of screen-detected CVD risk
factors or CVD risk varies by age, psoriasis severity and the
presence of psoriatic arthritis (PsA) and (iii) to calculate
the expected clinical benefits of normalizing modifiable risk
factors.
Materials and methods
Selection of general practices
We recruited patients from 13 general practices within North
West England sampled on list size and deprivation level based
on practice postcode.
Selection of participants
Participating practices were invited to identify adults with pso-
riasis using Read codes mapping to psoriasis and current pre-
scribing of psoriasis medications (Appendix 1). Exclusion
criteria were severe mental health problems, those without
capacity to consent, recently bereaved and terminally ill indi-
viduals. Eligible patients with psoriasis were sent an invitation
by their general practitioner (with a reminder when appropri-
ate) to attend their practice for CVD risk screening.
Data collection
Respondents were asked to self-complete several question-
naires before the assessment visit [Self-assessment Psoriasis
Area and Severity Index (PASI),5 Rose Angina Questionnaire,6
Psoriasis Epidemiology Screening Tool]7 and during the visit
(PsA questions, medical history, psoriasis history, social and
family history, therapy and comorbidity) with some additional
face-to-face questions asked by the nurse (alcohol and smok-
ing). Examination included height, weight (Seca 877; Seca,
Hamburg, Germany) and blood pressure (Omron 907 BPM;
Omron, Osaka, Japan). A fasting blood sample was taken for
glycated haemoglobin (HbA1c), lipids, glucose, liver and renal
function.
Known cardiovascular disease risk factors
Practice staff provided information about known CVD risk fac-
tors. We used this information along with information about
medication and self-reported risk factors to assess whether risk
factors were newly detected by screening.
Comparison with Health Survey for England
The prevalence of risk factors was compared with that in a
general population sample drawn from the Health Survey for
England 2011.8
Exposure and outcome definitions
‘PsA’ was defined as positive responses to any three out of the
five Psoriasis Epidemiology Screening Tool questions7 or a
positive response to the question ‘Have you ever been told
that you have arthritis associated with psoriasis?’.
‘Severe psoriasis’ was defined as a self-assessment PASI score
> 10 or currently receiving one or more psoriasis medications
(Appendix 2).
We used the following definitions for abnormal values also
used in the Health Survey for England.
‘Hypercholesterolaemia’ was defined as a positive response
to the question ‘Have you been told you have high cholesterol
or high blood fat levels?’, the use of lipid-lowering therapy or
total cholesterol > 5 mmol L1.
‘Diabetes’ was defined as a positive response to the ques-
tion ‘Have you ever been told by a doctor you have dia-
betes?’ or HbA1c ≥ 48 mmol mol
1 or the use of diabetes
medication.
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‘Hypertension’ was defined as a positive response to the
question ‘Have you been told you have high blood pressure?’,
systolic blood pressure > 140 mmHg, diastolic blood pressure
> 90 mmHg or use of antihypertensive medication.
‘Alcohol excess’ was defined as > 21 units per week in men
and > 14 units per week in women.
‘Suboptimal levels of risk factors on therapy’ were defined
as systolic blood pressure: > 140 mmHg, diastolic blood pres-
sure > 90 mmHg, cholesterol > 5 mmol L1 and HbA1c
≥ 53 mmol mol1.
‘Rheumatoid arthritis’ was defined as a positive response to
the question ‘Have you ever been told by a doctor that you
have rheumatoid arthritis?’.
Sample size calculations
We aimed to recruit 320 people to yield estimates of the
prevalence of CVD risk factors to within ~ 19% of the true
value for rarer factors and to within ~ 53% of the true value
for common factors.
Statistical methods
Data are reported as mean (SD) or median (range) depending
on data distribution. Groups were compared using v2-test or
Fisher’s exact test for categorical data and Student’s t-test or
the Mann–Whitney U-test for continuous data.
Sampling weights for the Health Survey for England data
were calculated by sex, ethnicity and 5-year age band, weights
being equal to the number of subjects in the stratum in the
psoriasis sample divided by the number of subjects in that
stratum in the Health Survey for England data. These weights
were used as sampling weights to standardize Health Survey
for England estimates to the age, ethnicity and sex distribution
of the psoriasis sample.
QRISK2 data were calculated by using STATA plugins using
the QRISK-2013 source code (ClinRisk Ltd., Nottingham,
U.K.). Using the QRISK2 calculator, the optimized CVD risk
was calculated using an ideal set of modifiable risk factors for
each individual (no smoking, cholesterol/high-density
lipoprotein ratio = 5, systolic blood pressure = 140 mmHg
and body mass index = 25 kg m2). The absolute change in
predicted risk through risk factor optimization was calculated
as the optimized risk minus the predicted risk before risk fac-
tor optimization.
P < 005 was considered statistically significant. All analyses
were performed using STATA 13 (StataCorp, College Station,
TX, U.S.A.).
Research ethics
The study was approved by the local research ethics commit-
tee [North West Research Committee, Greater Manchester East
(REC ref: 11/NW/0654)]. Written informed consent was
obtained from all participants.
Results
Invitations to attend were sent to 1446 patients, 287 of
whom (20%) enrolled. Overall, 22% of participants had
severe psoriasis defined by a high self-administered PASI
score (74% had an index of > 10) or use of disease-modi-
fying therapies (16% of participants) and one-third self-
reported PsA (Table 1).
More than one-third (35%) of patients were clinically
obese, 52% had a very high waist circumference (> 102 cm
for men; > 88 cm for women) and one in six (18%)
participants were current smokers (Table 1). Diabetes was
self-reported in 66% and two-thirds of these patients were
receiving diabetes medication. Approximately one-third self-
reported high cholesterol levels (29%) and high blood
pressure (33%) and over two-thirds of these were receiving
medication for these conditions [21% of the total cohort were
taking lipid-lowering medication (96% were taking a statin);
25% were taking antihypertensive medication].
A self-reported history of coronary or cerebrovascular dis-
ease or atrial fibrillation was reported by less than 10% of par-
ticipants (Table 1). In a separate assessment, the Rose Angina
Questionnaire elicited a history of myocardial infarction in
77% of participants, angina in 77% and intermittent claudi-
cation in 14%.
Prevalence of known and screen-detected (not previously
known) cardiovascular disease risk factors
The proportion of participants with known and screen-
detected (not known) CVD risk factors was as follows:
hypertension, 35% known and 13% screen-detected; hyper-
cholesterolaemia, 32% and 37%; diabetes, 66% and 31%;
and chronic kidney disease, 11% and 45% (Fig. 1). At least
one screen-detected risk factor was found in 48% of patients
and at least two risk factors were found in 21% of patients.
The prevalence of screen-detected risk factors did not vary sig-
nificantly by age, psoriasis severity or by the presence of self-
reported PsA (Table S1; see Supporting Information).
Comparison of prevalent cardiovascular disease risk
factors with Health Survey for England data
In an age-, sex- and ethnicity-weighted analysis, the preva-
lence of hypertension was 12% higher (P < 0001) in study
participants and the prevalence of hypercholesterolaemia was
7% lower (P = 003; Fig. 2) than in the general population.
As ciclosporin can cause hypertension we excluded patients
treated with this drug but the results were essentially
unchanged [n = 269, proportion with hypertension = 476%,
prevalence difference compared with Health Survey for Eng-
land data = 112%; 95% confidence interval (46–178)].
Some,9–11 but not all,12 previous studies have suggested
that methotrexate therapy is associated with a lower serum
cholesterol. In our study cohort, prevalent
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hypercholesterolaemia was lower in subjects taking methotrex-
ate compared with those not taking methotrexate (59% vs.
70%, P-value not significant). When we excluded patients
taking methotrexate from the psoriasis cohort, the prevalence
of hypercholesterolaemia was not statistically different from
the prevalence in the Health Survey for England (P = 008).
Level of control of risk factors in participants with known
risk factors
Among the study participants receiving treatment for CVD risk
factors, nearly half had suboptimal levels for blood pressure
(46%) and/or total cholesterol (46%) and one-quarter of par-
ticipants had suboptimal levels for glucose assessed by HbA1c
(26%) (Table S2; see Supporting Information).
Predicted 10-year risk and the anticipated response to
risk factor optimization
Using current National Institute for Health and Care Excellence
(NICE) guidelines, most patients with established CVD, type 1
diabetes, familial hypercholesterolaemia or renal impairment
are considered to be at high risk of CVD and unsuitable for
CVD risk calculation.13 In our study, participants not consid-
ered ‘high risk’ by NICE guidelines had an average QRISK2-
predicted 10-year CVD risk of 10%, meaning that over
10 years 10% would be expected to have a CVD event
(Table 2). Owing to the skewed risk distribution, just over
one-third of these patients (37%) were assessed to be at high
CVD risk using the 10-year CVD risk threshold of > 10%.13
The predicted average absolute reduction in 10-year risk
achieved through optimizing modifiable risk factors was 16%,
giving a number needed to treat (NNT) of 60 patients to pre-
vent one vascular event over 10 years.
Predicted lifetime risk and the anticipated response to
risk factor optimization
The mean predicted lifetime CVD risk estimated by QRISK2
was 35%. Overall, 13% of participants had a high lifetime
CVD risk of > 50%. Optimization of modifiable risk factors
would reduce the lifetime risk by 28%, giving an NNT of 36
patients to prevent one vascular event over a lifetime.
Predicted risk and response to risk factor optimization by
psoriasis severity and psoriatic arthritis
Compared with patients without self-reported PsA, those with
self-reported PsA had a 77% higher predicted 10-year CVD
risk assessed by QRISK2 (Table 2; 140% vs. 79%,
P = 0001). This higher risk largely disappeared after adjusting
for mean age, which was higher in those with self-reported
PsA (58 years vs. 51 years; analysis not shown).
The absolute reduction in 10-year and lifetime CVD risk,
predicted through risk factor optimization, was higher for par-
ticipants with severe psoriasis and self-reported PsA compared
with those without these conditions (Table 2).
In participants < 40 years of age, the average CVD risks
were much lower [10-year CVD risk = 07%, lifetime CVD
Table 1 Clinical characteristics of Identification and Management of
Psoriasis Associated ComorbidiTy study participants, n = 287
Variable Data
Age, years 53 (15)
Female sex 57
Index of multiple deprivation
for practice [median (range)]
19 (10–49)
Ethnicity
White British 94
Other white 3
Asian/Asian British 3
Weight, kg 81 (17)
BMI, kg m2 288 (59)
Obesity (BMI ≥ 30 kg m2) 35
Waist circumference, cm 96 (15)
Smoking
Current 18
Previous 39
Family history of premature
cardiovascular disease
19
Psoriasis severity and psoriatic arthritis
Severe psoriasisa 22
Self-administered PASI, median
(range); mean (SD)
34 (0–269); 42 (38)
Self-reported psoriatic arthritis 33
Self-reported cardiovascular disease risk factors
Hypercholesterolaemia 29
Hypertension 33
Diabetes 66
Cardiovascular diseaseb 84
Chronic kidney disease 11
Rheumatoid arthritis 77
Atrial fibrillation 56
Screening test results (all patients)
Total cholesterol, mmol L1 51 (12)
LDL cholesterol, mmol L1 31 (10)
HDL cholesterol, mmol L1 15 (04)
Non-HDL cholesterol, mmol L1 32 (12)
Triglycerides, mmol L1,
median (range)
13 (04–49)
Blood pressure, mmHg 130 (18)/78 (11)
Fasting plasma glucose, mmol L1 56 (53)
HbA1c mmol mol
1 383 (71)
eGFR, mL min1 89 (20)
BMI, body mass index; PASI, Psoriasis Area and Severity Index;
LDL, low-density lipoprotein; HDL, high-density lipoprotein;
eGFR, estimated glomerular filtration rate; HbA1c, glycated hae-
moglobin. Data are provided as percentages or mean (SD) values,
unless otherwise stated. aDefined as Self-administered PASI > 10
or use of disease-modifying therapy (psoralen–ultraviolet A,
methotrexate, ciclosporin, acitretin, fumaric acid esters, etaner-
cept, adalimumab, infliximab or ustekinumab). bSelf-reported
myocardial infarction, stroke, transient ischaemic attack, coro-
nary artery bypass surgery, coronary angioplasty or carotid
endarterectomy.
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risk = 31%, proportion at high risk over 10 years = 0% and
proportion at high risk over a lifetime = 4% (Table S3; see
Supporting Information)] and the NNTs were considerably
higher.
Discussion
Main findings
Screening patients with psoriasis recruited from primary care
showed that 37% of those not defined by NICE to be at ‘high
risk’ (such as those with prior myocardial infarction) had a
high 10-year CVD risk and that those with self-reported PsA
were at highest risk, mainly because they were older. At least
one screen-detected (previously unknown) CVD risk factor was
found in 48% of patients. The age- and sex-adjusted prevalence
of hypertension was higher than in the general population and
a high proportion of patients with known CVD risk factors had
suboptimal control of those risk factors. Finally, we showed
that optimization of modifiable CVD risk factors would be pre-
dicted to yield clinically relevant reductions in CVD event rates
particularly in those with self-reported PsA.
Fig 1. Proportion of Identification and Management of Psoriasis Associated ComorbidiTy (IMPACT) study participants with known and screen-
detected cardiovascular disease risk factors. Data are proportions of IMPACT study participants. ‘Known’ is the sum of (i) self-report, (ii)
medical or nursing staff knowing about this risk factor and (iii) medication for this risk factor. High blood pressure was defined as systolic
blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg. High cholesterol was defined as total cholesterol ≥ 5 mmol L1.
Diabetes was defined by high glycated haemoglobin ≥ 48 mmol mol-1. Chronic kidney disease was defined by low estimated glomerular
filtration rate < 60 mL min-1.
Fig 2. Prevalence of combined known and screen-detected cardiovascular risk factors in Identification and Management of Psoriasis Associated
ComorbidiTy (IMPACT) study and Health Survey for England participants. Data are proportions (95% confidence interval) of IMPACT study and
Health Survey for England participants with suboptimal risk factor status. Statistical significance for between-cohort comparisons is denoted by
*P < 005; **P < 0001. Prevalence of high cholesterol was not significant (P = 008) after excluding IMPACT study patients with psoriasis taking
methotrexate. High cholesterol was defined as self-reported hypercholesterolaemia or lipid-lowering therapy or total cholesterol > 5 mmol L1.
High blood pressure was defined as self-reported hypertension or use of antihypertensive therapy or systolic blood pressure ≥ 140 mmHg or
diastolic blood pressure ≥ 90 mmHg. High glycated haemoglobin (HbA1c) was defined as self-reported diabetes or diabetes therapy or HbA1c
≥ 48 mmol mol1. Obesity was defined as body mass index ≥ 30 kg m2. Smoking was defined as current use. Alcohol excess was defined as
> 21 units per week for men and > 14 units per week for women.
© 2016 The Authors. British Journal of Dermatology
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Prior population-based and primary care-based studies
This is the first primary care-based study reporting that CVD risk
factor screening augments the estimated prevalence of CVD risk
factors in psoriasis. It is the first to assess lifetime CVD risk and
the potential benefits of optimizing modifiable CVD risk factors.
The only previous European population-based CVD risk
factor prevalence study in psoriasis, was part of the larger Rot-
terdam study. It involved 262 participants with psoriasis aged
over 55 years (mean age 64 years) recruited from a suburb of
Rotterdam.14 Those with psoriasis had higher smoking preva-
lence (32% vs. 22%), higher body mass index (271 kg m2
vs. 265 kg m2), higher diastolic blood pressure and greater
use of lipid-lowering medication compared with study partici-
pants without psoriasis.
Three population-based studies from the U.S. National
Health and Nutrition Examination Survey (NHANES) com-
pared the prevalence of selected CVD risk factors in people
with and without psoriasis.15–17 One of these studies showed
that psoriasis was linked to a higher likelihood of prevalent
metabolic syndrome (driven by obesity and hypertension) but
with no higher risk for dyslipidaemia or diabetes, which was
largely confirmed in subsequent studies focusing on individual
risk factors.16,17
Prior studies in highly selected cohorts
A small number of studies have reported the prevalence of
screen-detected CVD risk factors in patients with psoriasis in
highly selected patient groups.18–21 These studies included
trial participants,20 disease registry participants18 and hospital-
ized patients,19,21 who are unlikely to be representative of
patients recruited from primary care.
Several large studies, some of which had been population-
based studies,22–25 have reported the prevalence of known CVD
risk factors.22,24–30 When compared with control populations
Table 2 QRISK2-predicted 10-year and lifetime cardiovascular disease (CVD) risks by the presence of severe psoriasis and psoriatic arthropathy
before and after theoretical CVD risk factor optimization in participants not considered to be high risk by National Institute for Health and Care
Excellence criteriaa
All patients
Severe psoriasis
P-value
Psoriatic arthropathy
P-valueYes No Yes No
n = 221 n = 47 n = 174 n = 76 n = 145
10-year risk
Proportion with high 10-year CVD risk
(> 10%)
37 28 39 015 51 29 0001
Proportion with high 10-year CVD risk
(> 20%)
17 17 15 07 26 12 0006
Mean (SD) risk before risk factor optimization 100 (113) 89 (115) 103 (113) 05 140 (138) 79 (91) 0001
Mean (SD) risk after risk factor optimization 84 (100) 72 (101) 87 (100) 04 118 (122) 66 (81) 0001
Absolute change in predicted risk through
risk factor optimization, absolute percentage
16 18 16 22 14
Estimated number needed to treat to prevent
one CVD event over 10 years
61 57 61 45 73
Lifetime risk
Proportion with lifetime risk > 50% 13 15 12 06 17 10 015
Mean (SD) risk before risk factor optimization 352 (133) 387 (161) 342 (122) 01 366 (149) 344 (123) 04
Mean (SD) risk after risk factor optimization 323 (117) 350 (140) 316 (109) 013 334 (134) 318 (107) 06
Absolute change in predicted risk through
risk factor optimization, absolute percentage
28 37 26 32 26
Estimated number needed to treat to prevent
one CVD event over a lifetime
36 26 38 31 38
Data are the proportion (%) of people predicted to develop myocardial infarction, angina, stroke or transient ischaemic attack over 10 years
(upper section of the table) over a lifetime (lower section of the table) unless stated. Lifetime risk is projected to age 95 years. Optimization
of risk factors: absence of smoking, cholesterol/high-density lipoprotein ratio = 5, systolic blood pressure = 140 mmHg and body mass
index = 25. Improvement in CVD risk is determined using the QRISK2 website calculators http://qrisk.org and http://www.qrisk.org/life-
time/. Absolute change in predicted risk through risk factor optimization has been calculated as predicted risk after risk factor optimization
minus predicted risk before risk factor optimization. Number needed to treat has been calculated as 100 divided by the absolute percentage
risk reduction. Severe psoriasis was defined as patients with Psoriasis Area and Severity Index score > 10, and those receiving psoralen–ultra-
violet A, methotrexate, ciclosporin, acitretin, fumaric acid esters, etanercept, adalimumab, infliximab or ustekinumab. Psoriatic arthropathy
was defined as positive responses to any three of the first five Psoriasis Epidemiology Screening Tool questions7 or a positive response to the
question ‘Have you ever been told that you have arthritis associated with psoriasis?’. aPatients with self-reported myocardial infarction, stroke,
transient ischaemic attack, coronary artery bypass surgery, coronary angioplasty, carotid endarterectomy, estimated glomerular filtration rate
< 60 mL min1, familial hypercholesterolaemia or type 1 diabetes mellitus were excluded from the analysis.
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(see below), patients with psoriasis had a higher likelihood
of hypertension,22,25–28,31,32 dyslipidaemia,22,25,28,29,31,32 dia-
betes,22,23,25,26,28,31,32 obesity22,26,31 smoking,22,26,32 renal
disease23,25,28 and metabolic syndrome.24,28,30 However,
control groups in these studies included people with ‘forms of
dermatitis’,26 other hospitalized patients21,28 and people taking
part in other research projects,21 which makes interpretation,
comparison and clinical implications uncertain.
Several other large studies have simply reported the preva-
lence of known CVD risk factors in patients with psoriasis
without a control group.33,34 While these studies have pro-
vided valuable data, they do not inform about the value of
primary care screening. Our study demonstrated that using a
standard approach to CVD screening of patients with psoriasis
who attend primary care is an effective means of identifying
individuals with CVD risk factors who would have been other-
wise missed.
Age, psoriasis severity and psoriatic arthritis
We showed that the proportion of patients with screen-
detected CVD risk factors was unrelated to age, psoriasis sever-
ity or the presence of self-reported PsA, suggesting that these
factors are unlikely to be clinically useful in increasing the
yield of abnormal risk factors from screening.
However, compared with patients without self-reported
PsA, those reporting PsA had a higher 10-year CVD risk lar-
gely because they were older. For this reason, older patients,
including those with self-reported PsA, may particularly bene-
fit from CVD screening and risk factor intervention.
Comparison with Health Survey for England data
When known and screen-detected risk factors were consid-
ered, hypertension was more prevalent in patients with psoria-
sis, which is in keeping with data from the Rotterdam study
and NHANES.14,17
We showed a lower prevalence of hypercholesterolaemia
in patients with psoriasis than in the general population
that could be explained by use of methotrexate. Even if the
prevalence of hypercholesterolaemia is lower in patients
with psoriasis than in the general population, this might
not diminish the importance of the condition because
more than one-third of these patients had screen-detected
hypercholesterolaemia.
Although we had an adequate sample size, our results did
not show statistically significant differences in the prevalence
of obesity, smoking or diabetes compared with the general
population.
Suboptimal management of known risk factors
We observed many patients with suboptimal management of
known risk factors. Previous studies have shown undertreat-
ment of CVD risk factors in patients with psoriasis20,35 and
one study suggested that hypertension is more difficult to
manage in these patients,29 perhaps because psoriasis or its
treatment somehow increases blood pressure or reduces
compliance with therapy.
Estimated lifetime cardiovascular disease risk and the
benefits of intervention
We considered lifetime CVD risk because younger high-risk
patients could be missed out using 10-year risk estimates, as
age dominates risk calculation. However, after excluding those
automatically designated as high risk, we found that a high
lifetime risk was present in only one in eight (13%) partici-
pants overall [and only one in 25 (4%) of those aged
< 40 years]. However, more than one in three participants
(37%) were at high 10-year CVD risk. The majority (20 of
28, 71%) of those at high lifetime risk would be detected by
having a high (> 10%) 10-year CVD risk. Therefore, the esti-
mation of lifetime risk does not appear to be particularly ben-
eficial in patients with psoriasis.
Risk identification and risk reduction
‘Health checks’ have recently come under criticism for fail-
ing to improve long-term health outcomes,36,37 perhaps
because of overmedication or social class biases in those
attending.38 An alternative explanation has been made by
our research team in a parallel study that recorded and anal-
ysed CVD consultations. They found that risk information
was seldom discussed with patients and instead practitioners
prioritized information collection.39 Thus, while the current
study has shown that screening identifies modifiable CVD
risk factors, caution is required before recommending this as
a strategy.
Strengths and limitations
Strengths of this study include the following: (i) we reported
how CVD risk factor screening influenced the detected preva-
lence of CVD risk factors; (ii) our data can inform policy on
primary care-based CVD screening; (iii) psoriasis severity was
assessed; (iv) the prevalence of important CVD risk factors
was established with clinically meaningful precision in impor-
tant subgroups; (v) we compared prevalence data with popu-
lation-based controls matched for age, sex and ethnicity; and
(vi) we assessed the benefits of optimizing risk factors within
10-year and lifetime time frames.
The limitations of this study include the following: (i) risk
factors were measured on one occasion, which may have led
to some misclassification, (ii) our cohort was largely white
limiting the generalizability of findings, (iii) the participation
rate was 20%; we suspect that patients who did not participate
would be more likely to have an adverse risk factor profile
than those who enrolled, and (iv) we did not validate diag-
noses of psoriasis or PsA.
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Clinical implications
Cardiovascular risk factor screening is a means of identifying a
high proportion of patients at high CVD risk, with screen-
detected risk factors and with suboptimally managed known
risk factors. However, these findings need to be considered
alongside those showing the limited response of clinicians to
identified risk before universal CVD screening for people with
psoriasis can be recommended.39
Conclusion
Screening for CVD risk factors in patients with psoriasis identi-
fied a high proportion of high-risk individuals with potentially
modifiable CVD risk factors in addition to a high proportion
with suboptimally managed known risk factors. These data
provide valuable augmenting information about the prevalence
of CVD risk factors and the potential value of primary care-
based screening of patients with psoriasis.
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Appendix 1:
Read codes and Read terms used to identify
study participants
2
Appendix 2:
Medication used to identify patients with
severe psoriasis
Psoralen and ultraviolet A therapy, methotrexate, ciclosporin,
acitretin, fumaric acid esters, etanercept, adalimumab, inflix-
imab or ustekinumab.
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